Clinical Trial Update: A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the immune response and safety of a multicomponent Shigella vaccine to prevent shigellosis in infants; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shigellosis

Drugs mentioned

• Shigella vaccine (multicomponent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diarrhoea | Phase 2 | Status: COMPLETED